文献速递临床试验与 GCP基础与转化研究

个体化围手术期血流动力学目标导向治疗在大型腹部手术中的随机对照试验方案(iPEGASUS)

Individualized, perioperative, hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-05-09

iPEGASUS 是一项多中心、国际、前瞻性随机对照试验,计划纳入 380 例接受大型腹部手术(包括内脏、泌尿和妇科手术)的患者,随机分为干预组和对照组。干预组围手术期采用基于脉压变异度(PPV)和脉搏轮廓分析(ProAQT® 设备)个体化优化心输出量的血流动力学治疗算法,对照组接受基于既定基础血流动力学治疗的当地标准护理。主要终点是术后 28 天内中重度并发症或死亡的复合终点。

要点

  • 干预组采用基于 PPV 和 ProAQT® 脉搏轮廓分析的个体化心输出量优化算法。
  • 主要终点为术后 28 天内中重度并发症或死亡的复合终点。
  • 试验计划纳入 380 例大型腹部手术患者,多中心国际随机对照设计。

核心结论

  • 该研究旨在评估围手术期个体化算法驱动的血流动力学优化能否降低大型腹部手术患者的死亡率和术后中重度并发症。

研究设计与样本

  • 多中心、国际、前瞻性随机对照试验,计划纳入 380 例接受大型腹部手术(包括内脏、泌尿和妇科手术)的患者。
  • 符合条件的患者在各参与中心被随机分配到两个治疗组。

主要发现

  • 原文未报告研究结果,本文为研究方案。

关键数值与推荐

  • 干预组:围手术期采用基于脉压变异度(PPV)和脉搏轮廓分析(ProAQT® 设备)个体化优化心输出量的血流动力学治疗算法。
  • 对照组:接受基于既定基础血流动力学治疗的当地标准护理。
  • 主要终点:术后 28 天内中重度并发症或死亡的复合终点。
  • 次要终点包括:中重度并发症总数(每患者及每种并发症);术后第 1、3、5、7、28 天至少发生一种并发症的情况(总计及每种并发症);第 7 天和第 28 天无机械通气、无血管升压药治疗、无肾脏替代治疗的存活天数,以及 ICU 和住院时间;6 个月后的死亡率和生活质量(EQ-5D-5L™ 问卷)。

临床怎么用

  • 原文未报告临床实践建议,本文为研究方案。

局限性

  • 原文未报告研究局限性,本文为研究方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative morbidity and mortality in patients undergoing surgery is high, especially in patients who are at risk of complications and undergoing major surgery. We hypothesize that perioperative, algorithm-driven, hemodynamic therapy based on individualized fluid status and cardiac output optimization is able to reduce mortality and postoperative moderate and severe complications as a major determinant of the patients' postoperative quality of life, as well as health care costs. METHODS/DESIGN: This is a multi-center, international, prospective, randomized trial in 380 patients undergoing major abdominal surgery including visceral, urological, and gynecological operations. Eligible patients will be randomly allocated to two treatment arms within the participating centers. Patients of the intervention group will be treated perioperatively following a specific hemodynamic therapy algorithm based on pulse-pressure variation (PPV) and individualized optimization of cardiac output assessed by pulse-contour analysis (ProAQT© device; Pulsion Medical Systems, Feldkirchen, Germany). Patients in the control group will be treated according to standard local care based on established basic hemodynamic treatment. The primary endpoint is a composite comprising the occurrence of moderate or severe postoperative complications or death within 28 days post surgery. Secondary endpoints are: (1) the number of moderate and severe postoperative complications in total, per patient and for each individual complication; (2) the occurrence of at least one of these complications on days 1, 3, 5, 7, and 28 in total and for every complication; (3) the days alive and free of mechanical ventilation, vasopressor therapy and renal replacement therapy, length of intensive care unit, and hospital stay at day 7 and day 28; and (4) mortality and quality of life, assessed by the EQ-5D-5L™ questionnaire, after 6 months. DISCUSSION: This is a large, international randomized controlled study evaluating the effect of perioperative, individualized, algorithm-driven ,hemodynamic optimization on postoperative morbidity and mortality. TRIAL REGISTRATION: Trial registration: NCT03021525 . Registered on 12 January 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Funcke S, Saugel B, Koch C, et al. Individualized, perioperative, hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS trial): study protocol for a randomized controlled trial. Trials. 2018. PMID: 29743101. doi:10.1186/s13063-018-2620-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。